Abstract: A method is provided that can include activating at least two wireless communication channels in parallel, between a first wireless transceiver and a second wireless transceiver. Each of the at least two wireless communication channels can operate at a different radio carrier frequency, and the first wireless transceiver may be part of a first vehicle. The method can also include transmitting, by the first wireless transceiver, common information in parallel on the at least two wireless communication channels to the second wireless transceiver and deactivating the at least two wireless communication channels.

Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

Abstract: A method and apparatus for jewelry organization is provided which has a body which is specially designed to avoid tangling of jewelry items and to house all types of jewelry at once, in an appealing fashion. The apparatus includes a body having an upper and lower surface, and at least one compartment formed in the upper surface defined as a channel sized to receive one or more items of jewelry. Each piece of jewelry is laid out along the path of the channel and does not mix or tangle with other pieces of jewelry. The upper surface of the body has an upwardly protruding knob. The knob may be frustoconical in shape and can hold at least one ring. The presently preferred knob is located in the center of the upper surface. The lower surface of the body may have a recess which is sized to receive a knob on a second jewelry organizer. The knob nests into the recess of another jewelry organizer so that the organizers can be stacked on top of one another.